PEAK PROCESSING LIMITED — Capital/Financing Update 2021

Jan 10, 2021

==> picture [595 x 148] intentionally omitted <==

ASX Announcement | 11 January 2021 Althea Group Holdings (ASX:AGH)

December sales exceed $1.19M with 90% monthly growth in UK

Investment Highlights:

• Althea achieved record sales of $1,190,473 in December 2020, an increase of 40% from November 2020, and the first time monthly sales have exceeded $1 million

• Australian sales were a record $902,466 for December 2020, an increase of 22% month-onmonth

• UK sales were a record $209,706 in December 2020, an increase of 90% from November 2020, and further evidence of Althea’s first-mover advantage in the territory

11 January 2021: Australian pharmaceutical company Althea Group Holdings Limited (ASX:AGH) (‘Althea’ or ‘the Company’) is pleased to provide an update on the Company’s Australian and UK operations and announce that Althea has achieved record sales across both of these markets during December 2020.

Althea recorded sales of $1,190,473 in December 2020, an increase of 40% from November 2020, and the first time monthly sales have exceeded $1 million.

Australian sales at an all-time high

Althea’s Australian operations generated record sales of $902,466 in December 2020, an increase of 22% month-on-month. The Company continues to gain market share in this territory and position itself as one of the country’s leading suppliers of medicinal cannabis.

Althea Australia recorded its highest average number of new patients and new Healthcare Professionals per business day in December, approximately 45.5 and 2.7, respectively.

Record UK sales with 90% monthly growth

Althea’s UK operations recorded sales of $209,706 in December 2020, an increase of 90% from November 2020, and further evidence of Althea’s first-mover advantage in the territory.

The UK sales results represent approximately 18% of Althea’s total revenue for the month of December, highlighting the importance of this growing market to the organisation.

Althea CEO, Josh Fegan, said: “We are extremely pleased to have closed out such a challenging year on a high note, and equally as pleased to have exceeded $1 million in monthly sales for the first time. With rapid growth and record sales occurring in both Australia and the UK, the Company continues to make great progress executing our strategy and we look forward to a monumental year in 2021.”

Invitation to participate in the share purchase plan

A reminder to all eligible shareholders that the Company’s Share Purchase Plan (SPP) is closing at 5:00pm (AEDT) on the 15th of January 2021 [see ASX announcement 21 December 2020].

==> picture [596 x 92] intentionally omitted <==

==> picture [595 x 148] intentionally omitted <==

The offer to participate in the SPP is made to Australian and New Zealand registered shareholders (including Custodians) who held shares at 7:00pm (AEDT) on 14 December 2020.

Please visit https://aghoffer.thereachagency.com/offer to view the offer document and complete the application form online.

-ENDS-

Authorised by: Robert Meissner, Company Secretary

For further information, please contact:

Althea Media Enquiries Investor Relations Josh Fegan Dan Francome Jane Morgan CEO & Managing Director Media Relations Investor Relations Partner M: 1300 70 20 20 P: +613 9650 5096 M: +61 405 555 618 E: contact@althea.life E: dfrancome@althea.life E: jm@janemorganmanagement.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea Group Holdings Ltd (ASX:AGH) is a global pharmaceutical company and supplier of medicinal cannabis. Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia, United Kingdom and Germany, with plans to expand the brand into emerging markets across the world.

To learn more, please visit: www.althea.life

==> picture [596 x 92] intentionally omitted <==